Regeneron to seek U.S. OK for COVID-19 cocktail to be used for prevention By John Miller
FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company s Westchester campus in Tarrytown
ZURICH (Reuters) -Regeneron is pursuing U.S. approval for its COVID-19 monoclonal antibody cocktail as a preventative treatment after it helped cut the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday.
REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week, and 93% after that, according to trial data released by the company.
How COVID antibody cocktails could help protect unvaccinated people theweek.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theweek.com Daily Mail and Mail on Sunday newspapers.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced Monday that it is prepared to ask the Food and Drug Administration for approval to use its Covid-19 antibody therapy as a preventative treatment.
ZURICH (Reuters) Regeneron is pursuing U.S. approval for its COVID-19 monoclonal antibody cocktail as a preventative treatment after it helped cut the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday.
REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week and 93% after that, according to trial data released by the company.
In a separate trial, Regeneron also said the treatment reduced overall risk of progressing to symptomatic COVID-19 by 31% and by 76% after the third day.
Regeneron has enlisted Switzerland s Roche and its massive biotech facility in South San Francisco to make around 2 million doses annually. The cocktail already has emergency U.S. approval for mild to moderate COVID-19 patients, and the companies are hoping the latest trials convince regulators to expand deployment.